• About
    • Adcendo
    • Leadership team
    • Board of Directors
  • Pipeline
    • Pipeline
    • Key publications
  • Patients
    • For Patients
    • Expanded Access Policy
  • Investors
    • Press releases and Media
    • Our investors
  • Careers & Values
  • Contact

Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180 (2016)

Apr 26, 2016

Recent Posts

  • Adcendo ApS Announces First Patient Dosed in Phase I/II ADCElerate1 Trial of ADCE-D01
  • Adcendo ApS to Present Data on its Clinical Stage ADCs ADCE-T02 and ADCE-D01 at the 2025 American Association for Cancer Research (AACR) Annual Meeting
  • Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team
  • Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02
  • Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline

Recent Comments

No comments to show.

Contact Us

Adcendo ApS
For all inquiries, please contact adcendo
via the e-mail address info@adcendo.com

Connect now  

Cookie Policy
Privacy Policy
Job Applicant Privacy Notice
© Adcendo ApS, All rights reserved 2025

Connect now